<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ORACEA - doxycycline capsule, delayed release pellets </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">40 mg</span>* </p>*<br>30* mg Immediate Release &amp; 10 mg Delayed Release beads <a href="http://"></a><a href="http://"></a><p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">KEEP OUT OF REACH OF CHILDREN</span></p>
<p>The dosage of ORACEA differs from that of doxycycline used to treat 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. To reduce the development of resistant bacteria as well as to 
maintain the effectiveness of other antibacterial drugs, ORACEA should be used 
only as indicated.</p>
<p>ORACEA is indicated for the treatment of only inflammatory lesions (<span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> 
and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>) of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> in adult patients.</p>
<p>This formulation of doxycycline has not been evaluated as an antibacterial in 
the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ORACEA (doxycycline, USP) capsules 40 mg are hard gelatin capsule 
shells filled with two types of doxycycline beads (30 mg immediate release and 
10 mg delayed release) that together provide a dose of 40 mg of anhydrous 
doxycycline (C<span class="Sub">22</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O<span class="Sub">8</span>).</p>
<p>The structural formula of doxycycline, USP is:<img alt="image of Oracea chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4e954825-3f60-4dbb-a1be-b146fe1acae4&amp;name=Oracea%20chemical%20structure.jpg"></p>
<p>with an empirical formula of C<span class="Sub">22</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O<span class="Sub">8</span>•H<span class="Sub">2</span>O and a molecular weight of 462.46. The chemical designation 
for doxycycline is 2-Naphthacenecarboxamide, 
4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, 
[4S-(4aα, 4aα, 5α, 5aα, 6a,12aα)]-, monohydrate. It is very slightly soluble in 
water.</p>
<p>Inert ingredients in the formulation are: hypromellose, iron oxide red, iron 
oxide yellow, methacrylic acid copolymer, polyethylene glycol, Polysorbate 80, 
sugar spheres, talc, titanium dioxide, and triethyl citrate. Active ingredients: 
Each capsule contains doxycycline, USP in an amount equivalent to 40 mg of 
anhydrous doxycycline.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">ORACEA capsules are not bioequivalent to other doxycycline products. The 
pharmacokinetics of doxycycline following oral administration of ORACEA was 
investigated in 2 volunteer studies involving 61 adults. Pharmacokinetic 
parameters for ORACEA following single oral doses and at steady-state in healthy 
subjects are presented in Table 1.</p>
<a name="i01e029e8-697c-46fa-8a23-839404653024"></a><table width="70%">
<caption><span>Table 1. Pharmacokinetic Parameters [Mean (± SD)] for ORACEA</span></caption>
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td>N<br>
</td>
<td>C<span class="Sub">max  </span><a href="#footnote-2"></a>*<br>(ng/mL)<span class="Sub"></span>
</td>
<td>Tmax  **<br><a href="#footnote-3"></a>(hr)</td>
<td>AUC0-∞ *<br>(ng∙hr/mL)</td>
<td>t1/2 <br>(hr) *<br>
</td>
</tr>
<tr>
<td>Single Dose<br>40 mg capsules</td>
<td>30<br>
</td>
<td>510 ±<br>220.7</td>
<td>3.00<br>(1.0-4.1)<br>
</td>
<td>9227 ±<br>3212.8</td>
<td>21.2 ±<br>7.6</td>
</tr>
<tr class="Last">
<td>Steady-State ***<br>40 mg capsules<br>
</td>
<td>31<br>
</td>
<td>600 ±<br>194.2</td>
<td>2.00<br>(1.0-4.0)<br>
</td>
<td>7543 ±<br>2443.9</td>
<td>23.2 ±<br>6.2</td>
</tr>
</tbody>
</table>*      Mean<br>**    Median<br>***  Day 7<br><br><br><br><a href="http://"></a>Absorption<p>In a single-dose food-effect study involving administration of 
ORACEA to healthy volunteers, concomitant administration with a 1000 calorie, 
high-fat, high-protein meal that included dairy products, resulted in a decrease 
in the rate and extent of absorption (Cmax and AUC) by about 45% and 22%, 
respectively, compared to dosing under fasted conditions. This decrease in 
systemic exposure can be clinically significant, and therefore if ORACEA is 
taken close to meal times, it is recommended that it be taken at least one hour 
prior to or two hours after meals.</p>
<a href="http://"></a><a href="http://"></a>Distribution<p>Doxycycline is greater than 90% bound to plasma proteins.</p>
<a href="http://"></a><a href="http://"></a>Metabolism<p>Major metabolites of doxycycline have not been identified. 
However, enzyme inducers such as barbiturates, carbamazepine, and phenytoin 
decrease the half-life of doxycycline.</p>
<a href="http://"></a><a href="http://"></a>Excretion<p>Doxycycline is excreted in the urine and feces as unchanged drug. 
It is reported that between 29% and 55.4% of an administered dose can be 
accounted for in the urine by 72 hours. Terminal half-life averaged 21.2 hours 
in subjects receiving a single dose of ORACEA.</p>
<a href="http://"></a><a href="http://"></a>Special Populations<a href="http://"></a><a href="http://"></a>Geriatric<p>Doxycycline pharmacokinetics have not been evaluated in geriatric 
patients.</p>
<a href="http://"></a><a href="http://"></a>Pediatric<p>Doxycycline pharmacokinetics have not been evaluated in pediatric 
patients (see <span class="Bold"><a href="#section-9">WARNINGS</a></span> 
section).</p>
<a href="http://"></a><a href="http://"></a>Gender<p>The pharmacokinetics of ORACEA were compared in 16 male and 14 
female subjects under fed and fasted conditions. While female subjects had a 
higher Cmax and AUC than male subjects, these differences were thought to be due 
to differences in body weight/lean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>.</p>
<a href="http://"></a><a href="http://"></a>Race<p>Differences in doxycycline pharmacokinetics among racial groups 
have not been evaluated.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span><p>Studies have shown no significant difference in serum half-life 
of doxycycline in patients with normal and severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. 
Hemodialysis does not alter the serum half-life of doxycycline.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span><p>Doxycycline pharmacokinetics have not been evaluated in patients 
with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>.</p>
<a href="http://"></a><a href="http://"></a>Gastric Insufficiency<p>In a study in healthy volunteers (N=24) the bioavailability of 
doxycycline is reported to be reduced at high pH. This reduced bioavailability 
may be clinically significant in patients with gastrectomy, gastric bypass 
surgery or who are otherwise deemed achlorhydric.</p>
<a href="http://"></a><a href="http://"></a>Drug Interactions<p>(see <span class="Bold"><a href="#section-10">PRECAUTIONS</a></span> section)</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section-4"></a><p></p>
<h1>MICROBIOLOGY</h1>
<p class="First">Doxycycline is a member of the tetracycline class of 
antibacterial drugs. The plasma concentrations of doxycycline achieved with 
ORACEA during administration (see <span class="Bold"><a href="#section-5">CLINICAL 
PHARMACOLOGY</a></span> and <span class="Bold"><a href="#section-13">DOSAGE AND 
ADMINISTRATION</a></span>) are less than the concentration required to treat 
bacterial diseases. <span class="Italics">In vivo</span> microbiological studies 
utilizing a similar drug exposure for up to 18 months demonstrated no detectable 
long-term effects on bacterial flora of the oral cavity, skin, intestinal tract, 
and vagina.</p>
<p>ORACEA should not be used for treating <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>, providing 
antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms 
associated with any bacterial disease.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-5"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">The safety and efficacy of ORACEA in the treatment of only 
inflammatory lesions (<span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>) of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> was evaluated in two 
randomized, placebo-controlled, multi-centered, double-blind, 16-week Phase 3 
studies involving 537 patients (total of 269 patients on ORACEA from the two 
studies) with <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> (10 to 40 <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span> and two or fewer <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>). 
Pregnant and nursing women, patients less than 18 years of age, and patients with 
ocular <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> and/or <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>/<span class="product-label-link" type="condition" conceptid="4146941" conceptname="Meibomianitis">meibomianitis</span> who require ophthalmologic 
treatment were excluded from study. Mean baseline lesion counts were 20 and 21 
for ORACEA and placebo patient groups respectively.</p>
<p>At Week 16, patients in the ORACEA group were evaluated using co-primary 
endpoints of mean reduction in lesion counts and a dichotomized static 
Investigator's Global Assessment of Clear or Almost Clear (defined as 1 to 2 
small <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> or <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>) when compared to the placebo group in both Phase 3 
studies.</p>
<a name="i604a7db2-ad60-4af3-859b-c2ff14ee3031"></a><table width="60%">
<caption><span>Table 2: Clinical Results of ORACEA versus Placebo</span></caption>
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td><br></td>
<td>
<span class="Bold">Study 1</span><br>
</td>
<td><br></td>
<td><br></td>
<td>
<span class="Bold">Study 2</span><br>
</td>
<td><br></td>
</tr>
<tr>
<td><br></td>
<td><span class="Bold">ORACEA<br>40 mg<br>N = 127<br></span></td>
<td><br></td>
<td><span class="Bold">Placebo<br>N = 124<br></span></td>
<td><span class="Bold">ORACEA<br>40 mg<br>N = 142<br></span></td>
<td><br></td>
<td><span class="Bold">Placebo<br>N = 144<br></span></td>
</tr>
<tr>
<td><span class="Bold">Mean Change in<br>Lesion Count from<br>Baseline<br></span></td>
<td>
<span class="Bold">-11.8</span><br>
</td>
<td><br></td>
<td>
<span class="Bold">-5.9</span><br>
</td>
<td>
<span class="Bold">-9.5</span><br>
</td>
<td>
<span class="Bold"></span><br>
</td>
<td>
<span class="Bold">-4.3</span><br>
</td>
</tr>
<tr class="Last">
<td><span class="Bold">No (%) of Subjects<br>Clear or Almost<br>Clear in the IGA  *<br></span></td>
<td><span class="Bold">39 (30.7%)</span></td>
<td><br></td>
<td><span class="Bold">24 (19.4%)</span></td>
<td><span class="Bold">21 (14.8%)</span></td>
<td><br></td>
<td><span class="Bold">9 (6.3%)</span></td>
</tr>
</tbody>
</table>
<br>*     Investigator's Global Assessment<br><br>Patients treated with ORACEA did not demonstrate significant improvement in 
<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> when compared to those treated with placebo.<br>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-6"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ORACEA is indicated for the treatment of only inflammatory 
lesions (<span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>) of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> in adult patients. No meaningful 
effect was demonstrated for generalized <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>) of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>. ORACEA 
has not been evaluated for the treatment of the erythematous, telangiectatic, or 
ocular components of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>. Efficacy of ORACEA beyond 16 weeks and safety 
beyond 9 months have not been established.</p>
<p>This formulation of doxycycline has not been evaluated in the treatment or 
prevention of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. ORACEA should not be used for treating bacterial 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, providing antibacterial prophylaxis, or reducing the numbers or 
eliminating microorganisms associated with any bacterial disease.</p>
<p>To reduce the development of drug-resistant bacteria as well as to maintain 
the effectiveness of other antibacterial drugs, ORACEA should be used only as 
indicated.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-7"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This drug is contraindicated in persons who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to 
doxycycline or any of the other tetracyclines.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-8"></a><p></p>
<h1>WARNINGS</h1>
<a href="http://"></a>Teratogenic effects1) 
<span class="Bold">Doxycycline, like other tetracycline-class antibiotics, can 
cause fetal harm when administered to a pregnant woman. If any tetracycline is 
used during pregnancy or if the patient becomes pregnant while taking these 
drugs, the patient should be informed of the potential hazard to the fetus and 
treatment stopped immediately.</span><br>ORACEA should not be used during 
pregnancy (see <span class="Bold"><a href="#section-10.10">PRECAUTIONS: 
Pregnancy</a></span>). 
2) 
<span class="Bold">The use of drugs of the tetracycline class during tooth 
development (last half of pregnancy, infancy, and childhood up to the age of 8 
years) may cause permanent discoloration of the teeth 
(yellow-gray-brown).</span> This adverse reaction is more common during 
long-term use of the drug but has been observed following repeated short-term 
courses. <span class="product-label-link" type="condition" conceptid="4131814" conceptname="Enamel hypoplasia">Enamel hypoplasia</span> has also been reported. <span class="Bold">Tetracycline 
drugs, therefore, should not be used during tooth development unless other drugs 
are not likely to be effective or are contraindicated.</span>3) 
All tetracyclines form a stable calcium complex in any bone-forming tissue. 
A decrease in fibula growth rate has been observed in premature human infants 
given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction was 
shown to be reversible when the drug was discontinued. <p class="First">Results of animal studies indicate that tetracyclines cross the 
placenta, are found in fetal tissues, and can cause retardation of skeletal 
development on the developing fetus. Evidence of embryotoxicity has been noted 
in animals treated early in pregnancy (see <span class="Bold"><a href="#section-10.10">PRECAUTIONS: Pregnancy</a></span> section).</p>
<a href="http://"></a><a href="http://"></a>Gastrointestinal effects<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with 
nearly all antibacterial agents and may range from mild to 
life-threatening.</span></p>
<p><span class="Bold">Therefore, it is important to consider this diagnosis in 
patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> subsequent to the administration of 
antibacterial agents.</span></p>
<p>Treatment with antibacterial agents alters the normal flora of the colon and 
may permit overgrowth of clostridia. Studies indicate that a toxin produced by 
Clostridium difficile is a primary cause of "antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>".</p>
<p>If a diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been established, therapeutic 
measures should be initiated. Mild cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually 
respond to discontinuation of the drug alone. In moderate to severe cases, 
consideration should be given to management with fluids and electrolytes, 
protein supplementation, and treatment with an antibacterial drug clinically 
effective against <span class="product-label-link" type="condition" conceptid="4307981" conceptname="Clostridium difficile colitis">Clostridium difficile colitis</span>.</p>
<a href="http://"></a><a href="http://"></a>Metabolic effects<p>The anti-anabolic action of the tetracyclines may cause an 
increase in BUN. While this is not a problem in those with normal renal 
function, in patients with significantly impaired function, higher serum levels 
of tetracycline-class antibiotics may lead to <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, and 
<span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>. If <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> exists, even usual oral or parenteral doses may 
lead to excessive systemic accumulations of the drug and possible liver 
toxicity. Under such conditions, lower than usual total doses are indicated, and 
if therapy is prolonged, serum level determinations of the drug may be 
advisable.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span><p><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> manifested by an exaggerated sunburn reaction 
has been observed in some individuals taking tetracyclines. Although this was 
not observed during the duration of the clinical studies with ORACEA, patients 
should minimize or avoid exposure to natural or artificial sunlight (tanning 
beds or UVA/B treatment) while using ORACEA. If patients need to be outdoors 
while using ORACEA, they should wear loose-fitting clothes that protect skin 
from sun exposure and discuss other sun protection measures with their 
physician.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-9"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a>General<p class="First">Safety of ORACEA beyond 9 months has not been established.</p>
<p>As with other antibiotic preparations, use of ORACEA may result in overgrowth 
of non-susceptible microorganisms, including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, 
ORACEA should be discontinued and appropriate therapy instituted. Although not 
observed in clinical trials with ORACEA, the use of tetracyclines may increase 
the incidence of <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>.</p>
<p>ORACEA should be used with caution in patients with a history of or 
predisposition to <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> overgrowth.</p>
<p><span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">Bacterial resistance</span> to tetracyclines may develop in patients using ORACEA. 
Because of the potential for drug-resistant bacteria to develop during the use 
of ORACEA, it should be used only as indicated.</p>
<a href="http://"></a><a href="http://"></a>Autoimmune Syndromes<p>Tetracyclines have been associated with the development of 
autoimmune syndromes. Symptoms may be manifested by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and 
<span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>. In symptomatic patients, liver function tests, ANA, CBC, and other 
appropriate tests should be performed to evaluate the patients. Use of all 
tetracycline-class drugs should be discontinued immediately.</p>
<a href="http://"></a><a href="http://"></a>Tissue Hyperpigmentation<p>Tetracycline class antibiotics are known to cause 
hyperpigmentation. Tetracycline therapy may induce hyperpigmentation in many 
organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity 
(teeth, mucosa, alveolar bone), sclerae and heart valves. Skin and oral 
<span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> has been reported to occur independently of time or amount of drug 
administration, whereas other <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> has been reported to occur upon 
prolonged administration. <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Skin pigmentation</span> includes diffuse <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> as 
well as over sites of <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span> or injury.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">Pseudotumor cerebri</span><p>Bulging fontanels in infants and <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span> 
in adults have been reported in individuals receiving tetracyclines. These 
conditions disappeared when the drug was discontinued.</p>
<a href="http://"></a><a href="http://"></a>Information for Patients<p><span class="Bold">See Patient Package Insert that accompanies this 
Package Insert for additional information to give patients.</span></p>
<ol>
<li><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> manifested by an exaggerated sunburn reaction has been 
observed in some individuals taking tetracyclines, including doxycycline. 
Patients should minimize or avoid exposure to natural or artificial sunlight 
(tanning beds or UVA/B treatment) while using doxycycline. If patients need to 
be outdoors while using doxycycline, they should wear loose-fitting clothes that 
protect skin from sun exposure and discuss other sun protection measures with 
their physician. Treatment should be discontinued at the first evidence of 
sunburn. 
</li>
<li>Concurrent use of doxycycline may render oral contraceptives less effective 
(see <span class="Bold"><a href="#section-10.7">Drug Interactions</a></span>). 
</li>
<li>Autoimmune syndromes, including drug-induced lupus-like syndrome, autoimmune 
<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> and <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span> have been observed with 
tetracycline-class antibiotics, including doxycycline. Symptoms may be 
manifested by <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>. Patients who experience such 
symptoms should be cautioned to stop the drug immediately and seek medical help. 

</li>
<li>Patients should be counseled about discoloration of skin, <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span>, teeth or 
gums that can arise from doxycycline therapy. 
</li>
<li>Take ORACEA exactly as directed. Increasing doses beyond 40 mg every morning 
may increase the likelihood that bacteria will develop resistance and will not 
be treatable by other antibacterial drugs in the future. 
</li>
<li>It is recommended that ORACEA not be used by pregnant or breast feeding 
women. (see <span class="Bold"><a href="#section-10.9">Carcinogenesis, 
Mutagenesis, Impairment of Fertility</a>, <a href="#section-10.10">Pregnancy</a></span> and <span class="Bold"><a href="#section-10.12">Nursing Mothers</a></span> sections). 
</li>
<li>It is recommended that ORACEA not be used by individuals of either gender 
who are attempting to conceive a child (see <span class="Bold"><a href="#section-10.9">Carcinogenesis, Mutagenesis, Impairment of 
Fertility</a>,</span> and <span class="Bold"><a href="#section-10.10">Pregnancy</a></span> sections). </li>
</ol>
<a href="http://"></a><a href="http://"></a>Laboratory Tests<p>Periodic laboratory evaluations of organ systems, including 
hematopoietic, renal and hepatic studies should be performed. Appropriate tests 
for autoimmune syndromes should be performed as indicated.</p>
<a href="http://"></a><a href="http://"></a>Drug Interactions<ol>
<li>Because tetracyclines have been shown to depress plasma <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> 
activity, patients who are on anticoagulant therapy may require downward 
adjustment of their anticoagulant dosage. 
</li>
<li>Since bacteriostatic drugs may interfere with the bactericidal action of 
penicillin, it is advisable to avoid giving tetracycline-class drugs in 
conjunction with penicillin. 
</li>
<li>The concurrent use of tetracycline and methoxyflurane has been reported to 
result in fatal renal toxicity. 
</li>
<li>Absorption of tetracyclines is impaired by bismuth subsalicylate, proton 
pump inhibitors, antacids containing aluminum, calcium or magnesium and 
iron-containing preparations. 
</li>
<li>Doxycycline may interfere with the effectiveness of low dose oral 
contraceptives. To avoid contraceptive failure, females are advised to use a 
second form of contraceptive during treatment with doxycycline. 
</li>
<li>There have been reports of <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span> (benign intracranial 
<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>) associated with the concomitant use of isotretinoin and 
tetracyclines. Since both oral retinoids, including isotretinoin and acitretin, 
and the tetracyclines, primarily minocycline, can cause increased intracranial 
pressure, the concurrent use of an oral retinoid and a tetracycline should be 
avoided. </li>
</ol>
<a href="http://"></a><a href="http://"></a>Drug/Laboratory Test Interactions<p>False elevations of urinary catecholamine levels may occur due to 
interference with the fluorescence test.</p>
<a href="http://"></a><a href="http://"></a>Carcinogenesis, Mutagenesis, Impairment of 
Fertility<p>Doxycycline was assessed for potential to induce carcinogenesis 
in a study in which the compound was administered to Sprague-Dawley rats by 
gavage at dosages of 20, 75, and 200 mg/kg/day for two years. An increased 
incidence of uterine <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> was observed in female rats that received 200 
mg/kg/day, a dosage that resulted in a systemic exposure to doxycycline 
approximately 12.2 times that observed in female humans who use ORACEA (exposure 
comparison based upon area under the curve (AUC) values). No impact upon tumor 
incidence was observed in male rats at 200 mg/kg/day, or in either gender at the 
other dosages studied. Evidence of oncogenic activity was obtained in studies 
with related compounds, i.e., oxytetracycline (adrenal and pituitary tumors) and 
minocycline (<span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid tumors</span>).</p>
<p>Doxycycline demonstrated no potential to cause genetic toxicity in an <span class="Italics">in vitro</span> point mutation study with mammalian cells 
(CHO/HGPRT forward mutation assay) or in an <span class="Italics">in vivo</span> 
micronucleus assay conducted in CD-1 mice. However, data from an <span class="Italics">in vitro</span> assay with CHO cells for potential to cause 
chromosomal aberrations suggest that doxycycline is a weak clastogen.</p>
<p>Oral administration of doxycycline to male and female Sprague-Dawley rats 
adversely affected fertility and reproductive performance, as evidenced by 
increased time for mating to occur, reduced sperm motility, velocity, and 
concentration, abnormal sperm morphology, and increased pre- and 
post-implantation losses. Doxycycline induced reproductive toxicity at all 
dosages that were examined in this study, as even the lowest dosage tested (50 
mg/kg/day) induced a statistically significant reduction in sperm velocity. Note 
that 50 mg/kg/day is approximately 3.6 times the amount of doxycycline contained 
in the recommended daily dose of ORACEA for a 60-kg human when compared on the 
basis of AUC estimates. Although doxycycline impairs the fertility of rats when 
administered at sufficient dosage, the effect of ORACEA on human fertility is 
unknown.</p>
<a href="http://"></a><a href="http://"></a>Pregnancy<a href="http://"></a><a href="http://"></a>Teratogenic Effects<a href="http://"></a><a href="http://"></a>Pregnancy Category D<p>(see <span class="Bold"><a href="#section-9">WARNINGS</a></span> 
section). Results from animal studies indicate that doxycycline crosses the 
placenta and is found in fetal tissues.</p>
<a href="http://"></a><a href="http://"></a>Nonteratogenic effects<p>(see <span class="Bold"><a href="#section-9">WARNINGS</a></span> 
section).</p>
<a href="http://"></a><a href="http://"></a>Labor and Delivery<p>The effect of tetracyclines on labor and delivery is 
unknown.</p>
<a href="http://"></a><a href="http://"></a>Nursing Mothers<p>Tetracyclines are excreted in human milk. Because of the 
potential for serious adverse reactions in infants from doxycycline, ORACEA 
should not be used in mothers who breastfeed. (see <span class="Bold"><a href="#section-9">WARNINGS</a></span> section).</p>
<a href="http://"></a><a href="http://"></a>Pediatric Use<p>ORACEA should not be used in infants and children less than 8 
years of age (see <span class="Bold"><a href="#section-9">WARNINGS</a></span> 
section). ORACEA has not been studied in children of any age with regard to 
safety or efficacy, therefore use in children is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-10"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<a href="http://"></a>Adverse Reactions in Clinical Trials of ORACEA<p class="First">In controlled clinical trials of adult patients with mild to 
moderate <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>, 537 patients received ORACEA or placebo over a 16-week period. 
The most frequent adverse reactions occurring in these studies are listed in 
Table 3.</p>
<a name="i9f4e8511-02d0-411c-89e4-fa5f8629300b"></a><table width="55%">
<caption><span>Table 3. Incidence (%) of Selected Adverse Reactions in Clinical Trials of ORACEA (n=269) vs. Placebo (n=268)</span></caption>
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td>
<span class="Bold">ORACEA</span><br>
</td>
<td>
<span class="Bold">Placebo</span><br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span><br>
</td>
<td>13 (4.8)<br>
</td>
<td>9 (3.4)<br>
</td>
</tr>
<tr>
<td>Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span><br>
</td>
<td>3 (1.1)<br>
</td>
<td>2 (0.7)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span><br>
</td>
<td>7 (2.6)<br>
</td>
<td>2 (0.7)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal Congestion</span><br>
</td>
<td>4 (1.5)<br>
</td>
<td>2 (0.7)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infection</span><br>
</td>
<td>5 (1.9)<br>
</td>
<td>1 (0.4)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span><br>
</td>
<td>5 (1.9)<br>
</td>
<td>3 (1.1)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>
</td>
<td>12 (4.5)<br>
</td>
<td>7 (2.6)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal Pain Upper</span><br>
</td>
<td>5 (1.9)<br>
</td>
<td>1 (0.4)<br>
</td>
</tr>
<tr>
<td>Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Distention</span><br>
</td>
<td>3 (1.1)<br>
</td>
<td>1 (0.4)<br>
</td>
</tr>
<tr>
<td>Abdmonial <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span><br>
</td>
<td>3 (1.1)<br>
</td>
<td>1 (0.4)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">Stomach Discomfort</span><br>
</td>
<td>3 (1.1)<br>
</td>
<td>2 (0.7)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span><br>
</td>
<td>3 (1.1)<br>
</td>
<td>0 (0)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span><br>
</td>
<td>8 (3.0)<br>
</td>
<td>2 (0.7)<br>
</td>
</tr>
<tr>
<td>Blood Pressure Increase<br>
</td>
<td>4 (1.5)<br>
</td>
<td>1 (0.4)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate Aminotransferase</span> Increase<br>
</td>
<td>6 (2.2)<br>
</td>
<td>2 (0.7)<br>
</td>
</tr>
<tr>
<td>Blood Lactate Dehydrogenase Increase<br>
</td>
<td>4 (1.5)<br>
</td>
<td>1 (0.4)<br>
</td>
</tr>
<tr>
<td>Blood Glucose Increase<br>
</td>
<td>3 (1.1)<br>
</td>
<td>0 (0)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span><br>
</td>
<td>4 (1.5)<br>
</td>
<td>0 (0)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span><br>
</td>
<td>4 (1.5)<br>
</td>
<td>1 (0.4)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span><br>
</td>
<td>3 (1.1)<br>
</td>
<td>0 (0)<br>
</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="4172302" conceptname="Sinus headache">Sinus Headache</span><br>
</td>
<td>3 (1.1)<br>
</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>
<br>Note:  Percentages based on total number of study participants in each treatment group.<br><br><a href="http://"></a>Adverse Reactions for Tetracyclines<p>The following adverse reactions have been observed in patients 
receiving tetracyclines at higher, antimicrobial doses:</p>
<p>Gastrointestinal: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, 
<span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, and inflammatory lesions (with <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>) in the 
anogenital region. Hepatotoxicity has been reported rarely. Rare instances of 
<span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> and <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcerations</span> have been reported in patients receiving 
the capsule forms of the drugs in the tetracycline class. Most of the patients 
experiencing <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> and/or <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulceration</span> took their medication 
immediately before lying down. (see <span class="Bold"><a href="#section-13">DOSAGE AND ADMINISTRATION</a></span> section).</p>
<p>Skin: maculopapular and erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>. <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span> has been 
reported but is uncommon. <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> is discussed above. (see <span class="Bold"><a href="#section-9">WARNINGS</a></span> section).</p>
<p><span class="Bold">Renal toxicity:</span> Rise in BUN has been reported and is 
apparently dose-related. (see <span class="Bold"><a href="#section-9">WARNINGS</a></span> section).</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, 
<span class="product-label-link" type="condition" conceptid="4101602" conceptname="Henoch-Schonlein purpura">anaphylactoid purpura</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, and exacerbation of 
<span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
<p>Blood: <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> have 
been reported.</p>
<br>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-11"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In case of overdosage, discontinue medication, treat 
symptomatically, and institute supportive measures. Dialysis does not alter 
serum half-life and thus would not be of benefit in treating cases of 
<span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">THE DOSAGE OF ORACEA DIFFERS FROM THAT OF 
DOXYCYCLINE USED TO TREAT <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span>. EXCEEDING THE RECOMMENDED DOSAGE MAY 
RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS INCLUDING THE DEVELOPMENT OF 
RESISTANT MICROORGANISMS.</span></p>
<p>One ORACEA Capsule (40 mg) should be taken once daily in the morning on an 
empty stomach, preferably at least one hour prior to or two hours after 
meals.</p>
<p>Efficacy beyond 16 weeks and safety beyond 9 months have not been 
established.</p>
<p>Administration of adequate amounts of fluid along with the capsules is 
recommended to wash down the capsule to reduce the risk of esophageal irritation 
and ulceration. (see <span class="Bold"><a href="#section-11">ADVERSE 
REACTIONS</a></span> section).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">ORACEA (beige opaque capsule printed with CGPI 40) containing 
doxycycline, USP in an amount equivalent to 40 mg of anhydrous doxycycline. 
Bottle of 30 (<span class="Bold">NDC 54868-5676-0</span>).</p>
<a href="http://"></a><a href="http://"></a>Storage<p>All products are to be stored at controlled room temperatures of 
l5°C-30°C (59°F-86°F) and dispensed in tight, light-resistant containers (USP). 
Keep out of reach of children.</p>
<a href="http://"></a><a href="http://"></a><p>Patent Information: U.S. Patents 5,789,395; 5,919,775 and patents 
pending.</p>
<p>Manufactured by:<br>CardinalHealth<br>Winchester, KY 40391</p>
<p>Marketed by:<br>CollaGenex Pharmaceuticals, Inc.<br>Newtown, PA 18940</p>
<p>May 26, 2006</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">ORACEA Capsule, 40 mg</p>
<p><img alt="image of Oracea 40 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4e954825-3f60-4dbb-a1be-b146fe1acae4&amp;name=Oracea%2040%20mg%20package%20label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ORACEA 		
					</strong><br><span class="contentTableReg">doxycycline capsule, delayed release pellets</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5676(NDC:64682-009)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOXYCYCLINE</strong> (DOXYCYCLINE) </td>
<td class="formItem">DOXYCYCLINE</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">brown (beige) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CGPI;40</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5676-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA050805</td>
<td class="formItem">09/29/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>4d2f8129-74e5-4e84-8257-827b160a743d</div>
<div>Set id: 4e954825-3f60-4dbb-a1be-b146fe1acae4</div>
<div>Version: 1</div>
<div>Effective Time: 20091230</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
